Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.
TheStreet's biotech columnist offers his own report card on biotech stocks.
hen a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.